Form 4: Atara Biotherapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Atara Biotherapeutics' CEO, AnhCo Nguyen, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On May 16, 2025, AnhCo Nguyen, the President and CEO of Atara Biotherapeutics, sold 3,276 shares of common stock at a price of $6.763 per share.
- The sale was executed to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.
- Following the transaction, Nguyen directly owns 70,847 shares of Atara Biotherapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't convey any strong positive or negative sentiment about the company's performance or future prospects.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based awards like restricted stock units. This transaction is not necessarily indicative of the executive's sentiment towards the company's future prospects.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of stock sale transaction. |
| 05/20/2025 | Date of signature on the Form 4 filing. |
Keywords
Atara Biotherapeutics, AnhCo Nguyen, stock sale, Form 4, tax withholding, restricted stock units, ATRA, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.